Pfizer's 32% Q3 revenue growth drops to 14% when excluding COVID products. Underlying growth not as strong as expected! Wall Street doesn't like this.
Pfizer's 32% Q3 revenue growth drops to 14% when excluding COVID products. Underlying growth not as strong as expected! Wall Street doesn't like this.
Nobody wants their poison!